Profile data is unavailable for this security.
About the company
Axim Biotechnologies, Inc. is a vertically integrated research and development company. The Company is focused on improving the landscape for the diagnosis of ophthalmological conditions such as dry eye disease (DED) through rapid diagnostic tests. Its core competencies include development of rapid lateral flow immunoassays, reagents, and monoclonal antibody development for such assays. Its product categories include Eye Health, wherein the Company acquired two FDA cleared tests for dye eye disease and has internally developed a third assay; and SARS-CoV-2 neutralizing antibody tests. The Company is focused on developing a proprietary diagnostic platform that can be adapted to test for a variety of analytes including SARS-Cov-2, Lactoferrin, IgE, Lacritin, and MMP-9. Its platform capability can also be applied to rapid testing for vaccine candidates. Its platform can also be used to enable point-of-care detection for one or more cancers using a unique cancer biomarker, QSOX1-L.
- Revenue in USD (TTM)92.90k
- Net income in USD-4.14m
- Incorporated2010
- Employees6.00
- LocationAxim Biotechnologies Inc6191 Cornerstone Court, E, Suite 114SAN DIEGO 92121United StatesUSA
- Phone+1 (212) 751-0001
- Fax+1 (775) 786-6755
- Websitehttps://aximbiotech.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regen BioPharma Inc | 236.57k | -882.60k | 957.95k | 1.00 | -- | -- | -- | 4.05 | -0.1079 | -0.1079 | 0.0297 | -0.5897 | 1.04 | -- | 3.82 | 236,570.00 | -407.33 | -104.36 | -- | -- | -- | -- | -392.01 | -275.00 | -- | -1.36 | -- | -- | 0.4416 | 18.79 | -58.11 | -- | -- | -- |
| PaxMedica Inc | 0.00 | -17.66m | 1.09m | 6.00 | -- | -- | -- | -- | -7.54 | -7.54 | 0.00 | -0.2324 | 0.00 | -- | -- | 0.00 | -594.25 | -755.77 | -2,502.49 | -- | -- | -- | -- | -- | -- | -11,785.74 | -- | -- | -- | -- | -23.56 | -- | -- | -- |
| Herborium Group, Inc. | 340.33k | -318.65k | 1.09m | 2.00 | -- | -- | -- | 3.21 | -0.3492 | -0.3492 | 0.3672 | -1.16 | 2.32 | 3.89 | 25.94 | -- | -216.97 | -490.56 | -- | -- | 58.31 | 56.36 | -93.63 | -186.81 | 0.0331 | -39.14 | -- | -- | 19.45 | -18.15 | 120.44 | -- | -- | -- |
| Axim Biotechnologies Inc | 92.90k | -4.14m | 1.21m | 6.00 | -- | -- | -- | 13.00 | -0.0163 | -0.0163 | 0.0003 | -0.0324 | 0.0233 | -- | -- | 15,483.33 | -103.73 | -154.34 | -- | -390.73 | 16.94 | -- | -4,451.97 | -36,362.71 | -- | -3.14 | -- | -- | 345.05 | -27.38 | -29.10 | -- | -- | -- |
| Zyversa Therapeutics Inc | 0.00 | -21.86m | 1.29m | 7.00 | -- | 0.1211 | -- | -- | -100.63 | -100.63 | 0.00 | 10.32 | 0.00 | -- | -- | 0.00 | -84.85 | -- | -140.95 | -- | -- | -- | -- | -- | -- | -21,828.74 | 0.00 | -- | -- | -- | -340.15 | -- | -- | -- |
| Trevena Inc | 546.00k | -34.04m | 1.47m | 23.00 | -- | -- | -- | 2.69 | -47.76 | -47.76 | 0.7121 | -27.27 | 0.017 | -- | -- | 23,739.13 | -105.83 | -55.93 | -130.71 | -66.35 | -190.29 | -- | -6,233.70 | -3,134.41 | -- | -18.32 | 3.43 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
| Panbela Therapeutics Inc | 0.00 | -28.56m | 1.54m | 7.00 | -- | -- | -- | -- | -84.64 | -84.64 | 0.00 | -2.18 | 0.00 | -- | -- | 0.00 | -197.23 | -215.89 | -3,522.07 | -476.38 | -- | -- | -- | -- | -- | -143.57 | -- | -- | -- | -- | 27.68 | -- | -- | -- |
| Kiromic Biopharma Inc | 0.00 | -26.21m | 1.55m | 35.00 | -- | -- | -- | -- | -19.73 | -19.73 | 0.00 | -3.35 | 0.00 | -- | -- | 0.00 | -167.49 | -161.04 | -- | -294.57 | -- | -- | -- | -- | -- | -7.22 | 1.74 | -- | -- | -- | 33.00 | -- | 8.52 | -- |
| Peak Bio Inc | 354.02k | -4.63m | 1.62m | -- | -- | -- | -- | 4.57 | -0.2066 | -0.2066 | 0.0135 | -0.9769 | 0.2192 | -- | -- | -- | -286.54 | -- | -- | -- | -- | -- | -1,307.11 | -- | -- | -4.85 | -- | -- | -39.46 | -- | 2.01 | -- | -- | -- |
| Aclarion Inc | 53.95k | -5.90m | 1.76m | 6.00 | -- | 0.87 | -- | 32.71 | -4.74 | -4.74 | 0.0146 | 0.20 | 0.0212 | -- | 3.59 | 8,991.67 | -231.70 | -- | -714.18 | -- | -51.53 | -- | -10,937.05 | -- | -- | -111.15 | 0.3212 | -- | 24.75 | -- | 34.38 | -- | -- | -- |
| Hi-Great Group Holding Co | 69.41k | -54.82k | 1.78m | -- | -- | -- | -- | 25.64 | -0.0005 | -0.0005 | 0.0007 | -0.0014 | 0.7459 | 0.6517 | -- | -- | -58.91 | -- | -- | -- | 54.26 | -- | -78.98 | -- | 0.0276 | -15.03 | -- | -- | -47.32 | -- | -3,789.70 | -- | -- | -- |
